President Donald Trump is trying to fast-track research into psychedelics as treatments, creating new opportunities and risks.

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

CVS will add Zepbound coverage on Oct. 1, and start covering Lilly’s newly approved Foundayo pill on June 1.